REFERENCES
1. Zuo F, Wang Y, Xu X, et al. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease. Metabolism. 2024;150:155724.
2. Brinkkoetter PT, Bork T, Salou S, et al. Anaerobic glycolysis maintains the glomerular filtration barrier independent of mitochondrial metabolism and dynamics. Cell Rep. 2019;27:1551-66.e5.
3. Nakamichi R, Hayashi K, Itoh H. Effects of high glucose and lipotoxicity on diabetic podocytes. Nutrients. 2021;13:241.
4. Hu H, Liang W, Ding G. Podocyte metabolic reprogramming and targeted therapy. J Am Soc Nephrol. 2026;37:619-33.
5. Zang N, Cui C, Guo X, et al. cGAS-STING activation contributes to podocyte injury in diabetic kidney disease. iScience. 2022;25:105145.
6. Choi SR, Lim JH, Kim MY, et al. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. Metabolism. 2018;85:348-60.
7. Wang J, Hu J, Hu H, et al. APT1-derived depalmitoylation of CD36 alleviates diabetes-induced lipotoxicity in podocytes. Int J Biol Sci. 2025;21:3852-66.
8. Chae SY, Kim Y, Park CW. Oxidative stress induced by lipotoxicity and renal hypoxia in diabetic kidney disease and possible therapeutic interventions: targeting the lipid metabolism and hypoxia. Antioxidants. 2023;12:2083.
9. Zuo FW, Liu ZY, Wang MW, et al. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice. Acta Pharmacol Sin. 2024;45:1019-31.
10. Nishi H, Nangaku M. Podocyte lipotoxicity in diabetic kidney disease. Kidney Int. 2019;96:809-12.
11. Liu X, Ducasa GM, Mallela SK, et al. Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome. Kidney Int. 2020;98:1275-85.
12. Fornoni A, Merscher S. Lipid metabolism gets in a JAML during kidney disease. Cell Metab. 2020;32:903-5.
13. Hu H, Wang J, Peng Z, Fan Y, Yang Q, Hu J. Dapagliflozin attenuates diabetes-induced podocyte lipotoxicity via ERRα-Mediated lipid metabolism. Free Radic Biol Med. 2025;234:178-91.
14. Requena B, Shabaka A, Lanzon B, et al. Lipidomics unveils critical lipid pathway shifts in Alport syndrome. Kidney Int Rep. 2025;10:2805-20.
15. Hu Y, Ye S, Kong J, et al. DOT1L protects against podocyte injury in diabetic kidney disease through phospholipase C-like 1. Cell Commun Signal. 2024;22:519.
16. Lee E, Lee HS. Peroxidase expression is decreased by palmitate in cultured podocytes but increased in podocytes of advanced diabetic nephropathy. J Cell Physiol. 2018;233:9060-9.
17. Wu M, Yang Z, Zhang C, et al. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Metabolism. 2021;118:154748.
18. Kim Y, Lim JH, Kim MY, et al. The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes. J Am Soc Nephrol. 2018;29:1108-27.
19. Luo Z, Chen Z, Hu J, Ding G. Interplay of lipid metabolism and inflammation in podocyte injury. Metabolism. 2024;150:155718.
21. Ryu JH, Ge M, Merscher S, et al. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice. PLoS One. 2019;14:e0211559.
22. Ge M, Molina J, Ducasa GM, et al. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Hum Mol Genet. 2021;30:182-97.
23. Fu Y, Sun Y, Wang M, et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. Cell Metab. 2020;32:1052-62.e8.
24. Loreth D, Sachs W, Meyer-Schwesinger C. The life of a kidney podocyte. Acta Physiol. 2025;241:e70081.
25. Fukusumi Y, Zhang Y, Yamagishi R, et al. Nephrin-binding Ephrin-B1 at the slit diaphragm controls podocyte function through the JNK pathway. J Am Soc Nephrol. 2018;29:1462-74.
26. Chang K, Hong F, Liu H, et al. FTO aggravates podocyte injury and diabetic nephropathy progression via m6A-dependent stabilization of ACC1 mRNA and promoting fatty acid metabolism. Biochem Pharmacol. 2025;235:116819.
27. Kim JJ, David JM, Wilbon SS, et al. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine. 2021;63:103162.
28. Ge M, Molina J, Kim JJ, et al. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. Elife. 2023;12:e83353.
29. Cansby E, Caputo M, Gao L, et al. Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease. JCI Insight. 2020;5:140483.
30. Zhang Y, Yao H, Li C, et al. Gandi capsule improved podocyte lipid metabolism of diabetic nephropathy mice through SIRT1/AMPK/HNF4A pathway. Oxid Med Cell Longev. 2022;2022:6275505.
31. Ito Y, Hsu MF, Bettaieb A, et al. Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury. Metabolism. 2017;76:56-69.
32. Sieber J, Jehle AW. Free fatty acids and their metabolism affect function and survival of podocytes. Front Endocrinol. 2014;5:186.
33. Carrasco AG, Izquierdo-Lahuerta A, Valverde ÁM, et al. The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868:159329.
34. Lee ES, Kang JS, Kim HM, et al. Dehydrozingerone inhibits renal lipotoxicity in high-fat diet-induced obese mice. J Cell Mol Med. 2021;25:8725-33.
35. Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21:79-85.
36. Tanaka Y, Kume S, Maeda S, et al. Overexpression of acetyl CoA carboxylase β exacerbates podocyte injury in the kidney of streptozotocin-induced diabetic mice. Biochem Biophys Res Commun. 2018;495:1115-21.
37. Locatelli M, Macconi D, Corna D, et al. Sirtuin 3 deficiency aggravates kidney disease in response to high-fat diet through lipotoxicity-induced mitochondrial damage. Int J Mol Sci. 2022;23:8345.
38. Nicholson RJ, Pezzolesi MG, Summers SA. Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease. Front Endocrinol. 2020;11:622692.
39. Kume S, Maegawa H. Lipotoxicity, nutrient-sensing signals, and autophagy in diabetic nephropathy. JMA J. 2020;3:87-94.
40. Cassis P, Locatelli M, Cerullo D, et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018;3:98720.
41. Park HS, Lim JH, Kim MY, et al. Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. J Transl Med. 2016;14:176.
42. Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21:2632.
43. Mitrofanova A, Mallela SK, Ducasa GM, et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat Commun. 2019;10:2692.
44. Lee E, Choi J, Lee HS. Palmitate induces mitochondrial superoxide generation and activates AMPK in podocytes. J Cell Physiol. 2017;232:3209-17.
45. Orellana JM, Kampe K, Schulze F, Sieber J, Jehle AW. Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling. Physiol Rep. 2017;5:e13287.
46. Wang Q, Zhao B, Zhang J, et al. Faster lipid β-oxidation rate by acetyl-CoA carboxylase 2 inhibition alleviates high-glucose-induced insulin resistance via SIRT1/PGC-1α in human podocytes. J Biochem Mol Toxicol. 2021;35:e22797.
47. Teng B, Schroder P, Müller-Deile J, et al. CIN85 deficiency prevents nephrin endocytosis and proteinuria in diabetes. Diabetes. 2016;65:3667-79.
48. Kruger C, Burke SJ, Collier JJ, Nguyen TT, Salbaum JM, Stadler K. Lipid peroxidation regulates podocyte migration and cytoskeletal structure through redox sensitive RhoA signaling. Redox Biol. 2018;16:248-54.
49. Xin R, Sun X, Wang Z, et al. Apocynin inhibited NLRP3/XIAP signalling to alleviate renal fibrotic injury in rat diabetic nephropathy. Biomed Pharmacother. 2018;106:1325-31.
50. Ke G, Chen X, Liao R, et al. Receptor activator of NF-κB mediates podocyte injury in diabetic nephropathy. Kidney Int. 2021;100:377-90.
51. He JY, Hong Q, Chen BX, et al. Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity. Acta Pharmacol Sin. 2022;43:342-53.
52. Cui Y, Shi Y, Bao Y, Wang S, Hua Q, Liu Y. Zingerone attenuates diabetic nephropathy through inhibition of nicotinamide adenine dinucleotide phosphate oxidase 4. Biomed Pharmacother. 2018;99:422-30.
53. Stanigut AM, Tuta L, Pana C, et al. Autophagy and mitophagy in diabetic kidney disease-a literature review. Int J Mol Sci. 2025;26:806.
54. Baechler BL, Bloemberg D, Quadrilatero J. Mitophagy regulates mitochondrial network signaling, oxidative stress, and apoptosis during myoblast differentiation. Autophagy. 2019;15:1606-19.
55. Martinez A, Lamaizon CM, Valls C, et al. c-Abl phosphorylates MFN2 to regulate mitochondrial morphology in cells under endoplasmic reticulum and oxidative stress, impacting cell survival and neurodegeneration. Antioxidants. 2023;12:2007.
56. Ni L, Yuan C. The mitochondrial-associated endoplasmic reticulum membrane and its role in diabetic nephropathy. Oxid Med Cell Longev. 2021;2021:8054817.
57. Xue H, Li P, Luo Y, et al. Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice. Phytomedicine. 2019;54:240-7.
58. Wang X, Zhao J, Li Y, Rao J, Xu G. Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression. Front Immunol. 2022;13:1090989.
59. Wang M, Chen Z, Tang Z, Tang S. Natural products derived from traditional Chinese medicines targeting ER stress for the treatment of kidney diseases. Ren Fail. 2024;46:2396446.
60. Liu Q, Guo S, Tong Y, et al. Renal lipotoxicity in diabetic and obesity-associated kidney diseases: Molecular mechanisms and therapeutic targeting. Diabetes Obes Metab. 2026;28:60-82.
61. Cha JJ, Hyun YY, Lee MH, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. 2013;154:2144-55.
62. Li Z, Tan D, Lin J, et al. Podocyte TLR4 deletion alleviates diabetic kidney disease through prohibiting PKCδ/SHP-1-dependent ER stress and relieving podocyte damage and inflammation. J Adv Res. 2026;82:845-62.
63. Lan C, Li Y, Weng Z, et al. TLR4 mediates lipotoxic β-cell dysfunction by inhibiting the TMEM24/PI3K/AKT pathway. Acta Biochim Biophys Sin. 2025;57:1684-95.
64. Gao J, Wu Y, Cai X, Zhao H, Xing J. Therapeutic potential of natural medicines in diabetic kidney disease: restoring lipid homeostasis via lipophagy modulation. Front Pharmacol. 2025;16:1665339.
65. Han Y, Xiong S, Zhao H, et al. Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy. Cell Death Dis. 2021;12:1031.
66. Li XZ, Jiang H, Xu L, et al. Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway. Biochem Pharmacol. 2021;192:114675.
67. Attie AD, Schueler KM, Keller MP, et al. Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy. Lab Invest. 2021;101:935-41.
68. Hatje FA, Wedekind U, Sachs W, et al. Tripartite separation of glomerular cell types and proteomes from reporter-free mice. J Am Soc Nephrol. 2021;32:2175-93.
69. Lei C, Li M, Qiu Y, et al. Asparaginyl endopeptidase protects against podocyte injury in diabetic nephropathy through cleaving cofilin-1. Cell Death Dis. 2022;13:184.
70. Zhang C, Zhao H, Yan Y, et al. LncRNA evf-2 exacerbates podocyte injury in diabetic nephropathy by inducing cell cycle re-entry and inflammation through distinct mechanisms triggered by hnRNPU. Adv Sci. 2024;11:e2406532.
71. Sunilkumar S, Yerlikaya EI, Toro AL, et al. Podocyte-specific expression of the stress response protein REDD1 is necessary for diabetes-induced podocytopenia. Diabetes. 2025;74:398-408.
72. Alonazi AS, Aloraini RM, Albulayhi LM, et al. Macrophage depletion alleviates immunosenescence in diabetic kidney by modulating GDF-15 and Klotho. Int J Mol Sci. 2025;26:3990.
73. Barutta F, Bellini S, Mastrocola R, et al. Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. Br J Pharmacol. 2018;175:4371-85.
74. Sun H, Li H, Yan J, et al. Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease. Nat Commun. 2022;13:1600.
75. Boi R, Bergwall L, Ebefors K, Bergö MO, Nyström J, Buvall L. Podocyte geranylgeranyl transferase type-I is essential for maintenance of the glomerular filtration barrier. J Am Soc Nephrol. 2023;34:641-55.
76. Zhong D, Chen J, Qiao R, et al. Genetic or pharmacologic blockade of mPGES-2 attenuates renal lipotoxicity and diabetic kidney disease by targeting Rev-Erbα/FABP5 signaling. Cell Rep. 2024;43:114075.
77. Kong Y, Feng W, Zhao X, et al. Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney. Theranostics. 2020;10:10415-33.
78. Chikatimalla R, Trivedi YV, Ruhela N, et al. Statins and kidney health: exploring cardiovascular benefits, renal protection, and risks in chronic kidney disease. Postgrad Med. 2025;137:588-600.
79. Huang CC, Chou CA, Chen WY, et al. Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPARγ/CD36 pathway in obese mice. Int J Mol Sci. 2021;22:12408.
80. Ye T, Zhang J, Wu D, et al. Empagliflozin attenuates obesity-related kidney dysfunction and NLRP3 inflammasome activity through the HO-1-adiponectin axis. Front Endocrinol. 2022;13:907984.
81. Hosokawa K, Takata T, Sugihara T, et al. Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules. Int J Mol Sci. 2019;21:190.
82. Sun J, Zhang X, Wang S, et al. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway. Diabetol Metab Syndr. 2024;16:38.
83. Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24:8732.
84. Hu Q, Qu C, Xiao X, et al. Flavonoids on diabetic nephropathy: advances and therapeutic opportunities. Chin Med. 2021;16:74.
85. Sulaiman MK. Molecular mechanisms and therapeutic potential of natural flavonoids in diabetic nephropathy: Modulation of intracellular developmental signaling pathways. Curr Res Pharmacol Drug Discov. 2024;7:100194.
86. Zheng Y, Ye X, Han X, Geng W, Zhao L, Meng D. Immunomodulatory roles of quercetin in diabetic nephropathy: targeting inflammation, oxidative stress, and ferroptosis. Front Pharmacol. 2025;16:1687677.
87. Ren G, Jiao P, Yan Y, Ma X, Qin G. Baicalin exerts a protective effect in diabetic nephropathy by repressing inflammation and oxidative stress through the SphK1/S1P/NF-κB signaling pathway. Diabetes Metab Syndr Obes. 2023;16:1193-205.
88. Cao Y-L, Lin J-H, Hammes H-P, et al. Flavonoids in treatment of chronic kidney disease. Molecules. 2022;27:2365.
89. Lin CL, Hsu YC, Huang YT, et al. A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO Mol Med. 2019;11:e9828.
90. Liebisch M, Wolf G. Role of epigenetic changes in the pathophysiology of diabetic kidney disease. Glomerular Dis. 2024;4:211-26.
91. Qu H, Liu X, Zhu J, et al. Dock5 deficiency promotes proteinuric kidney diseases via modulating podocyte lipid metabolism. Adv Sci. 2024;11:e2306365.
92. Ding S, Xu JL, Tong JY, et al. Brown adipose tissue alleviates podocyte apoptosis through NRG4 in a male mouse model of diabetic kidney disease. Diabetologia. 2025;68:1057-75.
93. Chen M, Fang Y, Ge Y, Qiu S, Dworkin L, Gong R. The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease. Redox Biol. 2024;72:103127.
94. Guo C, Ding Y, Yang A, et al. CHILKBP protects against podocyte injury by preserving ZO-1 expression. Cell Mol Life Sci. 2022;80:18.
95. Rogg M, Maier JI, Van Wymersch C, et al. α-Parvin defines a specific integrin adhesome to maintain the glomerular filtration barrier. J Am Soc Nephrol. 2022;33:786-808.
96. Lei X, Zhang BD, Ren JG, Luo FL. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway. Life Sci. 2018;206:77-83.
97. Chen X, Xiao J, Tao D, et al. Metadherin orchestrates PKA and PKM2 to activate β-catenin signaling in podocytes during proteinuric chronic kidney disease. Transl Res. 2024;266:68-83.
98. Njeim R, Gye H, Kelly CB, et al. A therapeutic lead compound for diabetic kidney disease with a unique lipophagy activation mechanism: SA-OR29. J Am Soc Nephrol. 2024;35:10.1681/asn.20248p613cev.
99. Njeim R, Awada B, Donow H, et al. Novel lipophagy inducers as potential therapeutics for lipid metabolism disorders. ACS Chem Biol. 2025;20:1406-16.
100. Li Q, Shi Z, Shi X, et al. Peroxisome proliferator-activated receptors in kidney diseases: a promising therapeutic target. Biomed Pharmacother. 2026;195:118983.
101. Suk Kang J, Son SS, Lee JH, et al. Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy. PLoS One. 2021;16:e0250666.
